Dr Jingwei Chen

Dr Jingwei Chen

Conjoint Associate Lecturer
  • Doctor of Philosophy (PhD) in School of Medicine, University of New South Wales, AU
  • Master of Science (MSc) in Department of Biology, University of York, UK
  • Bachelor of Science (BSc) in School of Life Science, University of Liverpool, UK
Medicine & Health
School of Clinical Medicine

Dr. Jingwei Chen is a post-doctoral research officer at the Children's Cancer Institute, Sydney, Australia. He graduated from the Univerisity of York, United Kingdom and completed his M.S thesis when he joined Professor Norman Maitland's Lab for adult cancer research at Cancer Research UK in 2015. He expanded his knowledge and research skills in children's cancer and obtained a PhD degree in 2020 from the University of New South Wales, Syndey in the field of pediatric oncology. His current research involves drug discovery, cancer genetics, epigenetics, cancer therapy, RNA methylation, and utilizing patient-derived xenograft (PDX) models to examine the efficacy of anticancer therapies. Ultimately, his work aims to identify molecular aberration underlying cancer progression and harness this information to find novel therapeutic targets and develop novel and targeted therapies for improving patient survival in pediatric cancer.

Children's Cancer Institute, Lowy Cancer Research Center
  • Journal articles | 2021
    Chen J; Nelson C; Wong M; Tee AE; Liu PY; La T; Fletcher JI; Kamili A; Mayoh C; Bartenhagen C; Trahair TN; Xu N; Jayatilleke N; Wong M; Peng H; Atmadibrata B; Cheung BB; Lan Q; Bryan TM; Mestdagh P; Vandesompele J; Combaret V; Boeva V; Wang JY; Janoueix-Lerosey I; Cowley MJ; MacKenzie KL; Dolnikov A; Li J; Polly P; Marshall GM; Reddel RR; Norris MD; Haber M; Fischer M; Zhang XD; Pickett HA; Liu T, 2021, 'Targeted therapy of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy', Clinical Cancer Research, 27, pp. 1438 - 1451, http://dx.doi.org/10.1158/1078-0432.CCR-20-3044
    Journal articles | 2021
    Naveed A; Cooper JA; Li R; Hubbard A; Chen J; Liu T; Wilton SD; Fletcher S; Fox AH, 2021, 'NEAT1 polyA-modulating antisense oligonucleotides reveal opposing functions for both long non-coding RNA isoforms in neuroblastoma', Cellular and Molecular Life Sciences, 78, pp. 2213 - 2230, http://dx.doi.org/10.1007/s00018-020-03632-6
    Journal articles | 2021
    Putra V; Hulme AJ; Tee AE; Sun JQJ; Atmadibrata B; Ho N; Chen J; Gao J; Norris MD; Haber M; Kavallaris M; Henderson MJ; McCarroll J; Trahair T; Liu T; Liu PY, 2021, 'The RNA-helicase DDX21 upregulates CEP55 expression and promotes neuroblastoma', Molecular Oncology, 15, pp. 1162 - 1179, http://dx.doi.org/10.1002/1878-0261.12906
    Journal articles | 2020
    Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T, 2020, 'Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma', International Journal of Cancer, 147, pp. 1928 - 1938, http://dx.doi.org/10.1002/ijc.32936
  • Conference Abstracts | 2019
    Chen J; Nelson C; Liu P; Tee AE; Atmadibrata B; MacKenzie K; Fletcher J; Trahair T; Polly P; Reddel R; Pickett H; Liu T, 2019, 'Efficacious targeting of TERT oncogene rearrangement with BET bromodomain inhibitor and proteasome inhibitor combination therapy', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-5209

Best Oral Presentation Awards 2019, AACBS

Early Career Researcher Oral Presentation First Price 2018, Kids Cancer Alliance, Cancer Council New South Wales

The Radhika V. Sreedhar Scholarship 2015